Back to News
Market Impact: 0.25
European Stocks Muted as Novartis Shares Fall Most on Record
Source: Bloomberg
Healthcare & BiotechCompany Fundamentals
European stocks were steady Tuesday, but Novartis AG weighed on the market after its third clinical-trial setback in one week. The repeated trial failures create a negative near-term catalyst for Novartis and underscore pipeline-development risk for the pharmaceutical company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
NVS-0.80
More News
- Newamsterdam Pharma stock hits 52-week low at 19.57 USD
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage